Quarterly report pursuant to Section 13 or 15(d)

Condensed Statements of Stockholders' Equity (Unaudited)

v3.24.1.1.u2
Condensed Statements of Stockholders' Equity (Unaudited) - USD ($)
Total
Common Stock
Additional Paid-In Capital
Accumulated Other Comprehensive Income (Loss)
Accumulated Deficit
Beginning balance at Dec. 31, 2022 $ 21,035,401 $ 4,224 $ 68,798,301 $ 104,718 $ (47,871,842)
Beginning balance, Shares at Dec. 31, 2022   4,224,294      
Stock-based compensation expense 123,273   123,273    
Issuance of common stock, pre-funded warrants and warrants, net of issuance costs 8,542,942 $ 972 8,541,970    
Issuance of common stock, pre-funded warrants and warrants, net of issuance costs, Shares   971,532      
Other comprehensive income 61,104     61,104  
Net loss (4,477,778)       (4,477,778)
Ending balance at Mar. 31, 2023 25,284,942 $ 5,196 77,463,544 165,822 (52,349,620)
Ending balance, Shares at Mar. 31, 2023   5,195,826      
Beginning balance at Dec. 31, 2023 $ 10,977,922 $ 6,186 77,871,584 877 (66,900,725)
Beginning balance, Shares at Dec. 31, 2023 6,186,280 6,186,280      
Stock-based compensation expense $ 53,434   53,434    
Issuance of common stock, pre-funded warrants and warrants, net of issuance costs 397,607 $ 291 397,316    
Issuance of common stock, pre-funded warrants and warrants, net of issuance costs, Shares   290,564      
Other comprehensive income (2,677)     (2,677)  
Net loss (4,649,635)       (4,649,635)
Ending balance at Mar. 31, 2024 $ 6,776,651 $ 6,477 $ 78,322,334 $ (1,800) $ (71,550,360)
Ending balance, Shares at Mar. 31, 2024 6,476,844 6,476,844